Simulations Plus (NASDAQ:SLP – Get Free Report) released its quarterly earnings results on Wednesday. The technology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02, Briefing.com reports. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The company had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. During the same period in the previous year, the firm earned $0.18 EPS. Simulations Plus’s revenue was up 19.9% on a year-over-year basis. Simulations Plus updated its FY25 guidance to $1.07 to $1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.
Simulations Plus Stock Down 0.9 %
Shares of Simulations Plus stock traded down $0.28 during trading on Friday, hitting $30.68. The stock had a trading volume of 276,597 shares, compared to its average volume of 130,076. The stock has a 50 day simple moving average of $33.20 and a 200 day simple moving average of $40.76. The company has a market capitalization of $613.91 million, a PE ratio of 64.50 and a beta of 0.69. Simulations Plus has a 1 year low of $29.37 and a 1 year high of $51.22.
Insider Transactions at Simulations Plus
In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $39.63, for a total value of $792,600.00. Following the transaction, the director now directly owns 3,521,592 shares of the company’s stock, valued at $139,560,690.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 60,750 shares of company stock valued at $2,145,055 over the last ninety days. Corporate insiders own 20.90% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Stock Report on SLP
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Further Reading
- Five stocks we like better than Simulations Plus
- Retail Stocks Investing, Explained
- Texas Roadhouse Stock Steering for New Highs This Year
- What is a Dividend King?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Best Aerospace Stocks Investing
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.